E-ISSN: 2320-1215
P-ISSN: 2322-0112

Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences

Current Research and Perspectives on Liposomes

Snehitha Megaji[1]
[1]Ganga Pharmacy College, Nizamabad, Telangana,

Review Article

Received: 22/09/2016
Revised: 25/09/2016
Accepted: 29/09/2016

***For Correspondence**

Snehitha Megaji, Ganga Pharmacy College, Nizamabad, Telangana, India; Tel: 917207557533; E-mail: snehi51@gmail.com

Keywords:
Liposomes, Nanocarriers, Chemotherapeutic, Drug delivery

E-mail: snehi51@gmail.com

ABSTRACT

A liposome is a tiny bubble spherical vesicle, made of cell membrane which are filled with drugs and used to deliver drugs diseases such as cancer used as a vehicle for administration of nutrients. The latest advances in liposome research allows liposomes to avoid detection by the body's immune system, such as the cells of reticuloendothelial system. These liposomes are known as "stealth liposomes". Targeted liposomes can target nearly any cell type in the body and deliver drugs that would otherwise be systemically delivered. Research on liposome technology has progressed from conventional vesicles to 'second-generation liposomes', in which long-circulating liposomes are obtained by modifying the lipid composition, size, and charge of the vesicle. The purpose of this article is to discuss the use of drug delivery systems, especially liposomes, to solve the problem of non-specific distribution of drugs through tumour targeting.

INTRODUCTION

Liposomes are small artificial vesicles of round shape that can be made from cholesterol and characteristic non-poisonous phospholipids [1,2]. Because of their size and hydrophobic and hydrophilic character, liposomes are promising frameworks for medication conveyance. Liposome properties contrast impressively with lipid creation, surface charge, size, and the strategy for arrangement [3-5]. Liposomes are non-poisonous, adaptable, biocompatible, totally biodegradable, and non-immunogenic for systemic and non-systemic organizations. Liposomes lessen the exposure of sensitive tissues to poisonous medications. Liposomes are widely utilized as bearers for various particles in restorative and pharmaceutical enterprises [6-10].

Moreover, modifiability of liposomes makes the more dynamic and exact focusing on conceivable. Attributable to these favorable circumstances, liposomes turn into the best medication conveyance framework with routine clinical use, a large portion of them are for cancer treatment [11-17].

Liposomes as Pharmaceutical Nanocarriers

Liposomes and micelles are the most broadly concentrated on and understood pharmaceutical nanocarriers [18-20]. Cholesterol and phospholipid atoms, that ordinarily shape cell layers, produce liposomes which are vesicular nanostructures. Lipid-or polymer-based conveyance of remedial specialist is the fundamental and basic nanotechnology stage which has found the most accomplishment in the facilities [21-25]. Pharmaceutical nanocarriers, for example, liposomes can possibly make new wellsprings of income for the pharmaceutical and biotech enterprises and will enhance the life cycle of medications. Pharmaceutical nanocarriers have made huge commitments to prescription and diagnostics and it will assist keep on revolutionizing these fields and further examinations [26-30].

Applications of PEG-liposomes

Clinical uses of liposomes as injectable medication bearers have been broadly examined because of their biocompatibility and powerful medication epitomizing property [31-37]. It is realized that the joining of polyethyleneglycol on liposome surface prompts the arrangement of a settled watery layer thickness around the nanoparticle because of an association between the PEG-polymer and water atoms, which keeps the fascination of opsonins, since serum proteins can't tie to the water accumulated on the surface of the liposomes. PEG-liposomes are the main polymercoated liposomes that have been endorsed for clinical use [38-40]. Regardless of the event of ABC marvel reported after PEG-liposomes applications, to the best of our insight no new covering atom demonstrated solid confirmation that they show prevalent qualities than those portrayed for PEG-liposomes [41-48].

Hybrid Liposomes

Hybrid liposomes initially created by Ueoka. Hybrid Liposomes can be set up by essentially ultrasonicating a blend of vesicular and micellar atoms in cradle arrangements, and contain no natural dissolvable dissimilar to ordinary liposomes [49,50]. The clinical chemotherapy with Hybrid liposomes with no medication to patients with lymphoma has been accounted for. Moreover, it has been shown that Hybrid liposomes could initiate apoptotic cell passing in tumor cells. The restorative impacts of Hybrid liposomes made out of L-α-dimyristoylphosphatidylcholine and sorbitan monolaurate including antitumor medications, for example, 1,3-bis(2-chloroethyl)- 1-nitrosourea have been seen on the development of glioma cells in vivo [51-56].

The typified divisions of mastic gum introduced higher cell reinforcement movement in contrast with the nonencapsulated ones. The lipid based bearers arranged by the TFE and EI strategies demonstrated better typifying effectiveness. From the test comes about it is inferred that the strategy for arrangement affects the release rate of constituents such as terpenes, pinenes, etc. [57-60].

In vitro uses of Chitosan Coated Liposomes

Delivering therapeutic compounds to target destinations is a major challenge in treatment of numerous ailments. Nanoparticles can be constituted of lipids, degradable or nondegradable polymers, metals and natural/inorganic mixes [61-64]. Covered liposomes made out of lecithin and high sub-atomic weight chitosan speak to an intriguing bearer for nanomedicine applications. The utilization of proper lecithin to chitosan proportions brings about a development of non-dangerous, exceedingly stable definitions ideally reasonable as medication conveyance frameworks. the ethanol diffusion in water, resulting in a precise and reproducible self-organization of lecithin and chitosan molecules and leading to homogenous Chitosan Coated Liposomes formulations [65,66]. The structure of nanoparticles is framed by ionic communications amongst lecithin and chitosan giving a conspicuous surface charge bringing about bio adhesive properties [67-70].

Liposomes and nanoparticles have risen as a promising potential medication conveyance framework. The various chemotherapeutic specialists have been planned and found for the treatment of different oncologic malignancies [71,72]. The potential liposomes and other nanoparticle plans hold in the utilization of tumour therapeutics for enhancing results in clinical medication. The liposomal chemotherapeutic plans depend on the ideas of passive targeting. The upgrades that dynamic focusing on can accomplish in particularly influencing tumour cells would just serve to enhance clinical results, changing the field of chemotherapy with these modified devices [73-80]. Current uses of liposomal details of chemotherapy have as of now demonstrated favourable circumstances in the treatment of growths when contrasted with routine chemotherapies [81-85].

Liposomes serves the hypo- sensitization towards the allergen by the insusceptible reaction and isolating of the flagging atom, histamine and keeps it from reaching the H1 receptor [86,87]. The liposomes on touching base at the objective site, discharge the monoclonal antibodies and histamines get stuck to the liposomes. This prompts a conformational change in the structure of the liposomes and radiates fluorescence. This could prompt the improvement of the inflammatory reactions in the end prompting anaphylactic response. The dose of allergen given to the patient must be lessened or totally halted to spare the individual's life. Thus the individual's life can be spared [88-91].

The hybrid nanoparticle, Hybrid Liposomes composed of 90 mol% L-α-Dimyristoylphosphatidylcholine and 10 mol% C12(EO)23, activity against the growth of NSCLC cells by causing apoptosis and arresting cells in the G0/G1 phase of the cell cycle through the inhibition of Act signaling. This study suggests that HL could be applied in novel nanomedicinal chemotherapy [92-96].

E-ISSN: 2320-1215
P-ISSN: 2322-0112

CONCLUSION

A liposomal delivery system requires a complete understanding of the physicochemical characteristics of the drug–liposome system in order to predict their behavior and stability in vivo. The concentration of the encapsulated BP without any special treatments, and to differentiate between the interior and exterior fractions. However, the robustness of the should be validated on liposomal formulations. Liposomes which forms nanotechnology science, also impressively and harmoniously, use the generalized nature of the liposomes themselves to therefore increase the efficacy, bioavailability, absorption, and delivery of these certain entrapped dietary and nutritional supplements. This generalized nature and makeup of liposomes, being composed of phospholipids, adroitly complements the natural lining of nearly every cell within the human body [97-100].

REFERENCES

1. Ichihara H, et al. Negatively Charged Cell Membranes-Targeted Highly Selective Chemotherapy with Cationic Hybrid Liposomes against Colorectal Cancer In Vitro and *In Vivo*. J Carcinog Mutagen. 2016;7:267.
2. Vaze OS Pharmaceutical Nanocarriers (Liposomes and Micelles) in Cancer Therapy. J Nanomed Nanotechnol. 2016;7:e138.
3. Wang X, et al. Active Targeting Liposomes: Promising Approach for Tumor-Targeted Therapy. J Bioequiv Availab. 2016;8:013-014.
4. Ichihara H, et al. Inhibitory Effects of Hybrid Liposomes on the Growth of Non-small Cell Lung Carcinoma Cells and Anti-invasive Activity by Ceramide Generation without any Drugs. J Carcinog Mutagen. 2015;6:230.
5. Khosroshahi ME, et al. In-vitro Application of Doxorubicin Loaded Magnetoplasmonic Thermosensitive Liposomes for Laser Hyperthermia and Chemotherapy of Breast Cancer. J Nanomed Nanotechnol. 2015;6:298.
6. Nunes SS, et al. The Use of Coating Agents to Enhance Liposomes Blood Circulation Time. J Mol Pharm Org Process Res. 2015;3:e120.
7. Nerome K, et al. The Usefulness of an Influenza Virus-Like Particle (VLP) Vaccine Produced in Silkworm Pupae and Virosomes and Liposomes Prepared by Chemical Means: From Virosome to VLP and the Future of Vaccines. J Gastrointest Dig Syst 2015;5:256.
8. Ichihara H, et al. Hybrid Liposomes inhibit the Growth and Angiogenesis in Human Breast Cancer Model. J Carcinog Mutagen. 2015;6:207.
9. Gortzi O, et al. Study of Antioxidant and Antimicrobial Activity of Chios Mastic Gum Fractions (Neutral, Acidic) Before and After Encapsulation in Liposomes. J Food Process. Technol 2014;5:355.
10. Mijan MC, et al. Vascular Shutdown and Pro-inflammatory Cytokine Expression in Breast Cancer Tumors after Photodynamic Therapy Mediated by Nano-sized Liposomes Containing Aluminium-Chloride-Phthalocyanine. J Nanomed Nanotechnol. 2014;5:218.
11. Venturini M, et al. Analysis of Operating Conditions Influencing the Morphology and *In vitro* Behaviour of Chitosan Coated Liposomes. J Nanomed Nanotechnol. 2014;5:211.
12. Watarai S, et al. Evaluation of Stearylamine-Modified Liposomes for the Oral Vaccine Adjuvant. J Infect Dis Ther. 2014;2:141.
13. Komizu Y, et al. Cell Cycle Arrest by Hybrid Liposomes for Human Lung Carcinoma Cells. J Carcinog Mutagen. 2014;5:157.
14. Sancini G, et al. Functionalization with TAT-Peptide Enhances Blood-Brain Barrier Crossing In vitro of Nanoliposomes Carrying a Curcumin-Derivative to Bind Amyloid-B Peptide. J Nanomed Nanotechol. 2013;4: 171.
15. Renuka Devi SK. Immunotherapy Monitoring Through Liposomes- An Altered Form of Bio-Sensing. J Aller Ther. 2012;3:122.
16. Azevedo EG, et al. Prolonged Blood Circulation Time of Antimony in Dogs with Visceral *Leishmania*sis from Liposomes with 175-nm Diameter. J Nanomedic Biotherapeu Discover. 2011;1:101.
17. Vaghasia N, et al. Liposomes for Targeting Cancer: One Step Closer to the Holy Grail of Cancer Therapeutics? J Nanomedic Biotherapeu Discover. 2011;1:105e.
18. Afergan E, et al. 31P-NMR and Differential Scanning Calorimetry Studies for Determining Vesicle's Drug Physical State and Fraction in Alendronate Liposomes. J Bioanal Biomed. 2010;2:125-131.
19. Li D, et al. Detection and Discrimination of Bioanalytes by Means of Colorimetric Sensor Array Based on Unmodified Gold and Silver Nanoparticles. J Bacteriol Parasitol 2016;7:283.

20. Ghosh S, et al. *Gloriosa superba* Mediated Synthesis of Silver and Gold Nanoparticles for Anticancer Applications. J Nanomed Nanotechnol. 2016;7:390.
21. Adhikari R. Applications of Upconversion Nanoparticles in Nanomedicine. J Nanomed Nanotechnol 2016;7:e141.
22. Mistry KR, et al. SLNs can Serve as the New Brachytherapy Seed: Determining Influence of Surfactants on Particle Size of Solid Lipid Microparticles and Development of Hydrophobised Copper Nanoparticles for Potential Insertion. J Chem Eng Process Technol. 2016;7:302.
23. Heidari A. Linear and Non-Linear Quantitative Structure-Anti-Cancer-Activity Relationship (QSACAR) Study of Hydrous Ruthenium (IV) Oxide (RuO_2) Nanoparticles as Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Anti-Cancer Nano Drugs. J Integr Oncol. 2016;5:e110.
24. Alaqad K, et al. Gold and Silver Nanoparticles: Synthesis Methods, Characterization Routes and Applications towards Drugs. J Environ Anal Toxicol. 2016;6:384.
25. Heidari A. Pharmacogenomics and Pharmacoproteomics Studies of Phosphodiesterase-5 (PDE5) Inhibitors and Paclitaxel Albumin-stabilized Nanoparticles as Sandwiched Anti-cancer Nano Drugs between Two DNA/RNA Molecules of Human Cancer Cells. J Pharmacogenomics Pharmacoproteomics. 2006;7:e153.
26. Sreelakshmy V, et al. Green Synthesis of Silver Nanoparticles from *Glycyrrhiza glabra* Root Extract for the Treatment of Gastric Ulcer. J Develop Drugs. 2016;5:152.
27. Israel LL, et al. Ultrasound-Mediated Surface Engineering of Theranostic Magnetic Nanoparticles: An Effective One-Pot Functionalization Process Using Mixed Polymers for siRNA Delivery. J Nanomed Nanotechnol. 2016;7:385.
28. Yadav JP, et al. Characterization and Antibacterial Activity of Synthesized Silver and Iron Nanoparticles using *Aloe vera*. J Nanomed Nanotechnol. 2016;7:384.
29. Dou Z, et al. Effect of Al_2O_3 Nanoparticles Doping on the Microwave Dielectric Properties of CTLA Ceramics. J Material Sci Eng. 2016;5:256.
30. Kumari VG, et al. Synthesis and Characterization of Pectin Functionalized Bimetallic Silver/Gold Nanoparticles for Photodynamic Applications. J Phys Chem Biophys. 2016;6: 221.
31. Jibowu T. The Formation of Doxorubicin Loaded Targeted Nanoparticles using Nanoprecipitation, Double Emulsion and Single Emulsion for Cancer Treatment. J Nanomed Nanotechnol. 2016;7:379.
32. A Heidari. Ab Initio and Density Functional Theory (DFT) Studies of Dynamic NMR Shielding Tensors and Vibrational Frequencies of DNA/RNA and Cadmium Oxide (CdO) Nanoparticles Complexes in Human Cancer Cells. J Nanomedine Biotherapeutic Discov. 2016;6:e144.
33. Li C, et al. Development and Validation of a Method for Determination of Encapsulation Efficiency of CPT-11/DSPE-mPEG2000 Nanoparticles. Med chem (Los Angeles). 2016;6:345-348.
34. Heidari A. Pharmaceutical and Analytical Chemistry Study of Cadmium Oxide (CdO) Nanoparticles Synthesis Methods and Properties as Anti- Cancer Drug and its Effect on Human Cancer Cells. Pharm Anal Chem Open Access. 2016;2:113.
35. Kumar B, et al. Aqueous Phase Lavender Leaf Mediated Green Synthesis of Gold Nanoparticles and Evaluation of its Antioxidant Activity. Biol Med (Aligarh). 2016;8: 290.
36. Stael C, et al. Optimized Synthesis of Multicomponent Nanoparticles for Removing Heavy Metals from Artificial Mine Tailings. Biol Med (Aligarh). 2016;8: 288.
37. Heidari A. Novel and Stable Modifications of Intelligent Cadmium Oxide (CdO) Nanoparticles as Anti-Cancer Drug in Formation of Nucleic Acids Complexes for Human Cancer Cells' Treatment. Biochem Pharmacol (Los Angel). 2016;5:207.
38. Stab J, et al. Flurbiprofen-loaded Nanoparticles Can Cross a Primary Porcine *In vitro* Blood-brain Barrier Model to Reduce Amyloid-ß42 Burden. J Nanomedine Biotherapeutic Discov. 2016;6:140.
39. Moradpour M, et al. Establishment of *in vitro* Culture of Rubber (Hevea brasiliensis) from Field-derived Explants: Effective Role of Silver Nanoparticles in Reducing Contamination and Browning. J Nanomed Nanotechnol. 2016;7:375.
40. Bhattacharyya S, et al. Modulating the Glucose Transport by Engineering Gold Nanoparticles. J Nanomedine Biotherapeutic Discov. 2016;6:141.
41. Francisco JC, et al. Acellular Human Amniotic Membrane Scaffold Loaded with Nanoparticles Containing 15d-PGJ2: A New System Local Anti-Inflammatory Treatment of Eye Diseases. J Clin Exp Ophthalmol. 2016;7:537.
42. Ghanbari M, et al. Study of the Cytotoxicity Effect of Doxorubicin-loaded/Folic acid-Targeted Super Paramagnetic Iron Oxide Nanoparticles on AGS Cancer Cell Line. J Nanomed Nanotechnol. 2016;7:368.
43. Pereira da Silva S, et al. Iron Oxide Nanoparticles Coated with Polymer Derived from Epoxidized Oleic Acid and Cis-1,2-Cyclohexanedicarboxylic Anhydride: Synthesis and Characterization. J Material Sci Eng. 2016;5:247.

44. Gandhi H, et al. Biological Synthesis of Silver Nanoparticles and Its Antibacterial Activity. J Nanomed Nanotechnol. 2016;7:366.
45. Murgueitio E, et al. Synthesis of Iron Nanoparticles using Extracts of Native Fruits of Ecuador, as Capuli (Prunus serotina) and Mortiño (*Vaccinium floribundum*). Biol Med (Aligarh). 2016;8:282.
46. AbouAitah KEA, et al. Mesoporous Silica Materials in Drug Delivery System: pH/Glutathione- Responsive Release of Poorly Water-Soluble Pro-drug Quercetin from Two and Three-dimensional Pore-Structure Nanoparticles. J Nanomed Nanotechnol. 2016;7:360.
47. AbouAitah KEA, et al. pH-controlled Release System for Curcumin based on Functionalized Dendritic Mesoporous Silica Nanoparticles. J Nanomed Nanotechnol. 2016;7:351.
48. Kumar P, et al. Synthesis of Dox Drug Conjugation and Citric Acid Stabilized Superparamagnetic Iron-Oxide Nanoparticles for Drug Delivery. Biochem Physiol. 2016;5:194.
49. Vinoda BM, et al. Photocatalytic Degradation of Toxic Methyl Red Dye Using Silica Nanoparticles Synthesized from Rice Husk Ash. J Environ Anal Toxicol. 2015;5:336.
50. El-Hussein A. Study DNA Damage after Photodynamic Therapy using Silver Nanoparticles with A549 cell line. J Nanomed Nanotechnol. 2016;7:346.
51. Yasir M, et al. Haloperidol Loaded Solid Lipid Nanoparticles for Nose to Brain Delivery: Stability and In vivo Studies. J Nanomedic Nanotechnol. 2015;S7:006.
52. Hajiyeva FV, et al. Luminescent Properties of Nanocomposites on the Basis of Isotactic Polypropylene and Zirconium Dioxide Nanoparticles. J Nanomedic Nanotechnol. 2015;S7:003.
53. Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
54. O'Connell MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J ClinOncol 1997;15:46-250.
55. Saltz LB, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001;6: 81-91.
56. Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350: 2335-2342.
57. Bokemeyer C, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22:1535-1546.
58. Peeters M, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer. 2013;108:503-511.
59. Van Blitterswijk WJ, et al. Comparative lipid analysis of purified plasma membranes and shed extracellular membrane vesicles from normal murine thymocytes and leukemic GRSL cells. BiochimBiophysActa. 1982;688:495-504.
60. Shinitzky M. Membrane fluidity in malignancy. Adversative and recuperative. BiochimBiophysActa. 1984;738: 251-261.
61. Hendrich AB, et al. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr Drug Targets. 2003;4:23-30.
62. Utsugi T, et al. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991;51:3062-3066.
63. Ran S, et al. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62:6132-6140.
64. Murayama T, et al. Colon carcinoma glycoproteins carrying alpha 2,6-linked sialic acid reactive with Sambucusnigra agglutinin are not constitutively expressed in normal human colon mucosa and are distinct from sialyl-Tn antigen. Int J Cancer. 1997;70:575-581.
65. Carstens MG, et al. Pharmaceutical Micelles: Combining Longevity, Stability, and Stimuli Sensitivity. Multifunctional Pharmaceutical Nanocarriers. Springer NewYork, USA. 2008.
66. Magadala P, et al. Multifunctional Polymeric Nanosystems for Tumor-Targeted Delivery. Multifunctional Pharmaceutical Nanocarriers, V Springer Newyork, USA. 2008.
67. Torchilin VP. Lipid-Based Parenteral Drug Delivery Systems: Biological Implications, in Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery. John Wiley and Sons. 2006;48-87.
68. Venditto VJ, et al. Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev. 2013;65:80-88.
69. Bregoli L, et al. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine. 2016;12:81-103.
70. Brown PD, et al. Nanomedicine: a pharma perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7:125-130.
71. Heidel JD, et al. Clinical developments in nanotechnology for cancer therapy. Pharm Res. 2011;28:187-199.
72. Wang AZ, et al. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198.

73. Anderson PM, et al. Mifamurtide in osteosarcoma--a practical review. Drugs Today (Barc). 2010;46:327-337.
74. Plummer R, et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer. 2011;104:593-598.
75. Hamaguchi T, et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res. 2010;16:5058-5066.
76. Jang SH, et al. Therapeutic Drug Monitoring: A Patient Management Tool for Precision Medicine. ClinPharmacolTher. 2015.
77. Krishna R, et al. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J PharmacolExpTher. 2001;298:1206-1212.
78. Davis T, et al. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine. Int J Nanomedicine. 2013;8:3479-3488.
79. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117-134.
80. van der Meel R, et al. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev. 2013;65:1284-1298.
81. Wei X, et al. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands. J Control Release. 2015;218:13-21.
82. Wei X, et al. A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. AngewChemInt Ed Engl. 2015;54:3023-3027.
83. Li C, et al. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy. J Drug Target. 2012;20:264-271.
84. Liu Y, et al. Multifunctional Tandem Peptide Modified Paclitaxel-Loaded Liposomes for the Treatment of Vasculogenic Mimicry and Cancer Stem Cells in Malignant Glioma. ACS Appl Mater Interfaces. 2015;7:16792-16801.
85. Yang Y, et al. Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes. Nanotechnology. 2013;24:405101.
86. Yang ZZ, et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;35:5226-5239.
87. Puvvada NA. Nanomedical platform for drug delivery. J NanomedNanotechnol. 2011;2:1-5.
88. Yiv SH, et al. Lipid spheres as attractive nanoscale drug delivery platforms for cancer therapy. J NanomedNanotechnol. 2012;3:1-6.
89. Gowda R, et al. Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy. J NanomedNanotechnol. 2013;4.
90. Babincová M,Cicmanec P, et al. AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry. 2002;55:17-19.
91. Landon CD, et al. Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. Open Nanomed J. 2011;3:38-64.
92. Tsalach A, et al. Tumor localization using magnetic nanoparticle-induced acoustic signals. IEEE Trans Biomed Eng. 2014;61:2313-2323.
93. Candido NM, et al. High efficacy in hyperthermia-associated with polyphosphate magnetic nanoparticles for oral cancer treatment. J NanomedNanotechol. 2014;3:1-11
94. Hassannejad Z, et al. Fabrication and characterization of magnetoplasmonic liposome carriers. NanosciTechnol. 2014;1:1-9.
95. Syed A, et al. Extracellular biosynthesis of monodispersed gold nanoparticles, their characterization, cytotoxicity assay, biodistribution and conjugation with the anticancer drug doxorubicin. J NanomedNanotechol. 2013;4:1-6.
96. Paasonen et al. Gold-embedded photosensitive liposomes for drug delivery: triggering mechanism and intracellular release. J Control Release. 2010;147:136-143.
97. Ma Z, et al. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm. 2005;293:271-280.
98. Liu X, et al. Chitosan-based biomaterials for tissue repair and regeneration. AdvPolymSci. 2011;244:81–128.
99. Sezer AD, et al. Topical drug delivery using chitosan nano- and microparticles. Expert Opin Drug Deliv. 2012;9:1129-1146.
100. Phetdee M, et al. Development of chitosan-coated liposomes for sustained delivery of tamarind fruit pulp's extract to the skin. Int J CosmetSci. 2008;30:285-295.